The following is the summary of “Effect of Implanted Defibrillator on Mortality in Patients With Chronic Kidney Disease” published in the February 2023 issue of Cardiovascular Disease by Al-Sadawi, et al.
Patients with chronic kidney disease (CKD) have a debatable benefit from implantable cardioverter defibrillators (ICDs). The goal of this meta-analysis was to assess whether or not ICDs reduced mortality in CKD patients. Research on the impact of ICD on all-cause mortality in individuals with CKD (estimated glomerular filtration rate 60 ml/min/1.73 m2) was sought out.
Time and publication status were not constraints on the search. Ovid MEDLINE, EMBASE, Scopus, Web of Science, Google Scholar, and EBSCO CINAHL were all consulted as part of the search. All-cause mortality was the key measure of success. Therefore, an annual minimum follow-up was necessary for consideration. A total of 834 studies were found, and 14 involving 70,661 patients were included in the analysis, with a median follow-up of 39 months (12 to 81 months). All-cause mortality was reduced for CKD patients with ICD (log hazard ratio [HR] 0.247, SE 0.101, P=0.015).
Overall impact test: Z=-2.431 (P=0.015); heterogeneity: df=13 (P<0.01), I2 = 97.057. Patients with CKD who did not require dialysis had a significantly decreased mortality (log HR -0.211, SE 0.095, P=0.026), and patients who had dialysis showed a similar tendency (log HR -0.262, SE 0.134, P=0.051). Patients with CKD who undergo ICD implantation experience a substantial reduction in mortality.
Source: sciencedirect.com/science/article/abs/pii/S0002914922011912
